| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Financial Results Release
|
29 Aug 2024 8:06AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Rebounded performance in the second half with Core nEBITDA up 48.7% on H1
- Full Year Net Revenue $155.0M, within 5% of the previous year
- Core nEBITDA at $17.2M, exceeding guidance
- Destocking activities by key customers in H1 placed strain on business
- Improved revenue in Components & Consumables and Disruptive Technologies in H2
- Capital Equipment segment experienced softer demand, expected to persist in H1 FY25
- Net Debt reduction of $4.7M to $32.9M
- Proforma Gross Margin for FY24 at 41.1%
- Guidance for FY25 Net Revenue is $160.0M to $165.0M, and Group nEBITDA $17.0M to $19.0M
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Appendix 4E and Annual Report
|
29 Aug 2024 8:06AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited reported a net revenue of $155.0 million for FY24.
- The company achieved a normalised EBITDA of $17.2 million.
- Proforma gross margin stood at 41.1%.
- Revenue for the Components & Consumables segment increased by approximately 25% in the third and fourth quarters compared to the first quarter.
- Significant progress was made in new technologies, including over 40% growth in Emitter Tips for Mass Spectrometry and a 140% increase in microbiopsy devices supplied for investigational use.
- Trajan's ESG program includes partnering with Carbonhound to establish a carbon emissions baseline and developing a 2024 ESG Strategy.
- The Capital Equipment segment reported a net revenue of $53.9 million and a normalised EBITDA of $9.7 million.
- Trajan launched its first environmental workflow solution, the CHRONECT Workstation, in August 2024.
- The company's efforts toward sustainability include redesigning sustainable packaging solutions and focusing on reducing emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Ceasing to be a substantial holder
|
19 Aug 2024 4:10PM |
$1.140 |
$0.260 |
fallen by
77.19%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Full Year Results and Investor Webinar Notification
|
13 Aug 2024 12:51PM |
$1.055 |
$0.260 |
fallen by
75.36%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Non-cash intangible asset impairment, FY guidance confirmed
|
1 Aug 2024 10:02AM |
$1.055 |
$0.260 |
fallen by
75.36%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited announced a non-cash impairment of intangible assets.
- The impairment is due to a $26.7M write-down, mainly related to Neoteryx goodwill and intangibles ($25.0M).
- The remaining $1.7M impairment relates to other microsampling related assets.
- Despite the impairment, there is a strong order demand for microsampling with a 29.8% increase in H2 over H1.
- The impairment will be recorded in the Full Year 2024 Financial Results, to be released on 29th August 2024.
- A technical breach of a financial covenant occurred due to the Neoteryx impairment but has since been resolved.
- The company's performance remains aligned with the financial guidance ranges provided in May.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change in substantial holding
|
29 Jul 2024 4:04PM |
$1.045 |
$0.260 |
fallen by
75.12%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change in substantial holding
|
10 Jul 2024 5:42PM |
$1.040 |
$0.260 |
fallen by
75%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Notification of cessation of securities - TRJ
|
1 Jul 2024 9:45AM |
$1.025 |
$0.260 |
fallen by
74.63%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change in substantial holding
|
14 Jun 2024 5:12PM |
$0.930 |
$0.260 |
fallen by
72.04%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
21 May 2024 3:52PM |
$0.920 |
$0.260 |
fallen by
71.74%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Becoming a substantial holder
|
15 May 2024 3:29PM |
$0.940 |
$0.260 |
fallen by
72.34%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Becoming a substantial holder
|
13 May 2024 6:04PM |
$0.810 |
$0.260 |
fallen by
67.90%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Release of shares from escrow
|
13 May 2024 8:19AM |
$0.740 |
$0.260 |
fallen by
64.86%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Trajan May 2024 Market Update
|
9 May 2024 8:26AM |
$0.905 |
$0.260 |
fallen by
71.27%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- TRJ continues to deliver revenue growth and expand its global footprint.
- Successful integration of recent acquisitions strengthens TRJ's product portfolio.
- Ongoing investments in R&D support innovation and new product development.
- The company is well positioned within the analytical sciences sector amid favorable market trends.
- TRJ maintains a focus on sustainability and ESG initiatives.
- The macroeconomic environment and customer demand dynamics are being closely monitored.
- Trajan aims to deliver long-term value to its shareholders through strategic execution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY24 Financial Results Presentation
|
27 Feb 2024 8:01AM |
$1.300 |
$0.260 |
fallen by
80%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue growth achieved through organic expansion and recent acquisitions.
- Resilient performance despite challenging global economic conditions.
- Strong demand in laboratory and analytical sciences markets.
- Focus on expanding product and services portfolio and operational efficiency.
- Positive EBITDA performance reported for H1 FY24.
- Ongoing investment in research and development to drive innovation.
- Commitment to long-term value creation and global market expansion.
- Management remains optimistic about future growth opportunities.
- Strategic priorities include core business growth and operational excellence.
- Detailed financial performance, management strategies, and FY24 outlook provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY24 Financial Results Release
|
27 Feb 2024 8:01AM |
$1.300 |
$0.260 |
fallen by
80%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY24 revenue growth driven by both acquisitions and organic performance.
- Strong contributions from Analytical Products and Solutions segments.
- Gross margin expanded due to improved product mix and operational efficiencies.
- North America and Europe showed particularly robust performance.
- Continued investment in R&D and integration of recent acquisitions.
- Positive financial outlook with ongoing focus on profitability improvement.
- Strategic focus remains on scientific innovation and global partnership expansion.
- Sustainable, long-term value creation is a key priority for the company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
H1 FY24 Appendix 4D and Interim Report
|
27 Feb 2024 8:01AM |
$1.300 |
$0.260 |
fallen by
80%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trajan Group Holdings Limited reported increased revenue for H1 FY24 compared to the previous year.
- The company specializes in analytical science and laboratory workflow solutions.
- The directors' report includes details on operations, financial performance, and strategic developments.
- There were no significant changes in the company's state of affairs during the period.
- No dividends were declared or paid for the half-year ending 31 December 2023.
- Trajan continues to pursue both organic growth and growth by acquisitions.
- The company's global presence and product portfolio have been expanded.
- The report outlines the company's risk management practices and financial position.
- There have been no significant events after the reporting period affecting the interim report.
- Trajan invests in research and development to support its strategy and innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
FY24 Half Year Results and Investor Webcast Notification
|
7 Feb 2024 8:20AM |
$1.050 |
$0.260 |
fallen by
75.24%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Trajan Shareholder Day Presentations
|
30 Oct 2023 8:26AM |
$1.320 |
$0.260 |
fallen by
80.30%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Change of Director's Interest Notice
|
24 Oct 2023 12:56PM |
$1.250 |
$0.260 |
fallen by
79.20%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Application for quotation of securities - TRJ
|
24 Oct 2023 11:38AM |
$1.250 |
$0.260 |
fallen by
79.20%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Results of 2023 Annual General Meeting
|
5 Oct 2023 11:42AM |
$1.295 |
$0.260 |
fallen by
79.92%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
2023 Annual General Meeting Chair Address and Presentation
|
5 Oct 2023 8:51AM |
$1.160 |
$0.260 |
fallen by
77.59%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Notification regarding unquoted securities - TRJ
|
3 Oct 2023 10:33AM |
$1.150 |
$0.260 |
fallen by
77.39%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$40 |
Trajan to Host Inaugural Shareholder Day
|
27 Sep 2023 10:49AM |
$1.200 |
$0.260 |
fallen by
78.33%
|
|
Call 1300 880 160
Start a chat
Schedule a call
